Erratum: Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials (Schizophrenia Bulletin (2015) DOI: 10.1093/schbul/sbu170);Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials

Schizophrenia Bulletin

Volumn 41, Issue 4, 2015, Pages 892-899

  Fusar Poli, Paolo ^a,b   Papanastasiou, Evangelos ^a   Stahl, Daniel ^a   Rocchetti, Matteo ^a,c   Carpenter, William ^d   Shergill, Sukhwinder ^a   McGuire, Philip ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

antipsychotics; negative symptoms; psychosis; schizophrenia; treatment

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL GLOBAL IMPRESSION SCALE; DEMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; NEGATIVE SYMPTOM RATING SCALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; PATHOPHYSIOLOGY; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA;

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84936753582     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbz071     Document Type: Erratum

References (55)

1. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182:193-204.
2. Carpenter W, Buchanan R. Domains of psychopathology relevant to the study of etiology and treatment of schizophrenia. In: Schulz SC, Tamminga CA, eds. Schizophrenia: Scientific Progress. New York: Oxford University Press; 1989:13-22.
3. Strauss JS, Carpenter WT, Bartko JJ. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;1:61-69.
4. Kraepelin E. Lecture III, Dementia Praecox. Lectures on Clinical Psychiatry. New York: William Wood; 1917:21-29.
5. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238-245.
6. Villalta-Gil V, Vilaplana M, Ochoa S, et al. Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients Schizophr Res. 2006;87:246-253.
7. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. Schizophr Res. 2009;113:189-199.
8. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97-100.
9. Lin CH, Huang CL, Chang YC, et al. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr Res. 2013;146:231-237.
10. Magliano L, Fadden G, Madianos M, et al. Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol. 1998;33:405-412.
11. Magliano L, Fadden G, Economou M, et al. Family burden and coping strategies in schizophrenia: 1-year follow-up data from the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol. 2000;35:109-115.
12. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279-293.
13. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
14. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull. 1985;11:440.
15. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet. 2012;379:2063-2071.
16. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol. 1996;11(suppl 2):3-11.
17. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry. 1988;145:578-583.
18. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl. 1995;92:24-30.
19. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373:31-41.
20. NICE. Psychological therapy and psychological interventions in the treatment and management of schizophrnenia: arts therapies. In: Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Vol National Clinical Guideline Number 82. Updated Edition ed. Leicester, London: The British Psychological Society & The Royal College of Psychiatrists; 2010:251-257.
21. Darbà J, Minoves A, Rojo E, Jimenez F, Rejas J. Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: A meta-analysis of randomized clinical trials. Rev Psiquiatr Salud Ment. 2011;4:126-143.
22. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197:174-179.
23. Rummel C, Kissling W, Leucht S. Antidepressants as addon treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. Schizophr Res. 2005;80:85-97.
24. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res. 2006;88:5-25.
25. Mller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17:793-823.
26. Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res. 2009;108:11-24.
27. Fitzgerald PB, Daskalakis ZJ. A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia. Can J Psychiatry. 2008;53:567-576.
28. Sarin F, Wallin L, Widerlv B. Cognitive behavior therapy for schizophrenia: A meta-analytical review of randomized controlled trials. Nord J Psychiatry. 2011;65:162-174.
29. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523-537.
30. Jones C, Cormac I, Silveira da Mota Neto J, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004;4:CD000524.
31. Mossler K, Chen X, Heldal TO, Gold C. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2011;12:CD004025.
32. McGrath J, Hayes R. Cognitive rehabilitation for people with schizophrenia and related conditions. Cochrane Database Syst Rev. 2000;3:CD000968.
33. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
34. Overall JE, Gorham DR. The Brief Psychiatric Rating-Scale. Psychol Rep. 1962;10:799-812.
35. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa city: University of Iowa; 1981.
36. Rosenthal R. Meta-analysis: A review. Psychosom Med. 1991;53:247-271.
37. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: NIMH Psychopharmacology Research Branch, Department of Health, Education and Welfare; 1976:218-222.
38. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-1900.
39. Everitt B. Modern Medical Statistics. London: Arnold; 2003.
40. Cooper H, Hedges LV, Valentine JC. Handbook of Research Synthesis and Meta-Analysis. New York: Russell Sage Foundation; 2009.
41. Steichen T. Nonparametric trim and fill analysis of publication bias in meta-analysis. Stata Technical Bulletin, StataCorp LP. 2001;10:57.
42. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557.
43. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31:2318-2325.
44. Levine SZ, Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res. 2013;145:125-127.
45. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32:1903-1910.
46. McGurk S, Twamley E, Sitzer D, McHugo G, Mueser K. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007;164:1791-1802.
47. Kurtz MM, Richardson CL. Social cognitive training for schizophrenia: A meta-analytic investigation of controlled research. Schizophr Bull. 2012;38:1092-1104.
48. Lepping P, Schnfeldt-Lecuona C, Sambhi RS, et al. A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. Acta Psychiatr Scand. 2014;130:326-341.
49. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75(suppl 1):8-14.
50. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006;32:234-237.
51. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. Wiley.com; 2012:57-60.
52. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567-620.
53. Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry. 2014;71:706-715.
54. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-9, W64.
55. de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70:1416-1423.